Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 3/20 | 0.34 |
| ▸ | CDK2 | P24941 | 3/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26685343 | 0.79 | IDH1 (0.34) | ALOX5 | |
| SCHEMBL906585 | 0.77 | CTH (0.35) | — | |
| SCHEMBL29444546 | 0.77 | CTH (0.35) | — | |
| SCHEMBL1041388 | 0.77 | HTR7 (0.33) | — | |
| SCHEMBL31691830 | 0.77 | HTR7 (0.30) | — | |
| SCHEMBL1814163 | 0.74 | GRM5 (0.32) | — | |
| SCHEMBL3508831 | 0.74 | IRAK4 (0.35) | — | |
| SCHEMBL1643042 | 0.74 | CYP2C19 (0.41) | — | |
| SCHEMBL13116849 | 0.74 | IRAK4 (0.35) | — | |
| SCHEMBL24333441 | 0.73 | TRPV3 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304577-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2025-10-02 | — | — | US | disclosed |
| EP-4522612-A1 | TYK2 INHIBITORS | Biogen MA Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023220046-A1 | TYK2 INHIBITORS | BIOGEN MA INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220046-A1 | TYK2 INHIBITORS | BIOGEN MA INC. (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304577-A1 | TYK2 INHIBITORS | TYK2, JAK2, JAK1 | CCNA2 1576/4885CDK2 220/4885CDK5 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.